Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deguchi, A.
Right arrow Articles by Weinstein, I. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deguchi, A.
Right arrow Articles by Weinstein, I. B.
Vol. 1, 803-809, August 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Provides a Biomarker for the Action of Exisulind and Related Agents That Activate Protein Kinase G 1

Atsuko Deguchi, Jae-Won Soh, Han Li, Rifat Pamukcu, W. Joseph Thompson and I. Bernard Weinstein2

Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032 [A. D., J-W. S., I. B. W.], and Cell Pathways, Inc., Horsham, Pennsylvania 19044 [H. L., R. P., W. J. T.]

Recent studies provide evidence that exisulind and two potent derivatives, CP461 and CP248, induce apoptosis in colon cancer cells by inhibiting cyclic GMP (cGMP)-specific phosphodiesterases (phosphodiesterases 2 and 5). This causes an increase in intracellular levels of cGMP, thus activating the cGMP-dependent protein kinase G (PKG), which then activates pathways that lead to apoptosis. To further examine this mechanism and to provide a potential in vivo biomarker for activation of this pathway, we examined phosphorylation of the vasodilator-stimulated phosphoprotein (VASP), a ubiquitously expressed endogenous substrate for PKG. We found that VASP was phosphorylated after treating SW480 colon cancer cells with exisulind, CP461, or CP248. CP248-induced VASP phosphorylation was inhibited by a specific PKG inhibitor but not by a protein kinase A inhibitor. The drug 3-(5'-hydroxymethyl-2'-furyl)-benzylindazole and nitric oxide donors that activate cellular guanylyl cyclase and thus increase cellular levels of cGMP also caused VASP phosphorylation. With all of these agents, the phosphorylation of VASP was associated with increased intracellular levels of cGMP and the induction of apoptosis. We also demonstrated direct in vivo phosphorylation of VASP with constitutively activated mutants of PKG. These results suggest that VASP phosphorylation can provide a useful endogenous cellular biomarker for anticancer agents that cause cGMP-mediated apoptosis.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Masood, A. Nadeem, S. J. Mustafa, and J. M. O'Donnell
Reversal of Oxidative Stress-Induced Anxiety by Inhibition of Phosphodiesterase-2 in Mice
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 369 - 379.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Cen, A. Deguchi, and I. B. Weinstein
Activation of Protein Kinase G Increases the Expression of p21CIP1, p27KIP1, and Histidine Triad Protein 1 through Sp1
Cancer Res., July 1, 2008; 68(13): 5355 - 5362.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Yang, G. Liu, S. I. Zakharov, A. M. Bellinger, M. Mongillo, and S. O. Marx
Protein Kinase G Phosphorylates Cav1.2 {alpha}1c and {beta}2 Subunits
Circ. Res., August 31, 2007; 101(5): 465 - 474.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. Xiao, A. Deguchi, G. G. Gundersen, B. Oehlen, L. Arnold, and I. B. Weinstein
The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization
Mol. Cancer Ther., January 1, 2006; 5(1): 60 - 67.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Deguchi, S. W. Xing, I. Shureiqi, P. Yang, R. A. Newman, S. M. Lippman, S. J. Feinmark, B. Oehlen, and I. B. Weinstein
Activation of Protein Kinase G Up-regulates Expression of 15-Lipoxygenase-1 in Human Colon Cancer Cells
Cancer Res., September 15, 2005; 65(18): 8442 - 8447.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Shimizu, M. Suzui, A. Deguchi, J. T. E. Lim, D. Xiao, J. H. Hayes, K. P. Papadopoulos, and I. B. Weinstein
Synergistic Effects of Acyclic Retinoid and OSI-461 on Growth Inhibition and Gene Expression in Human Hepatoma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6710 - 6721.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Deguchi, W. J. Thompson, and I. B. Weinstein
Activation of Protein Kinase G Is Sufficient to Induce Apoptosis and Inhibit Cell Migration in Colon Cancer Cells
Cancer Res., June 1, 2004; 64(11): 3966 - 3973.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman
Frontiers in Cancer Prevention Research
Cancer Res., September 15, 2003; 63(18): 5649 - 5655.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.